UPDATE 1-Amgen pays $71 mln to settle Enbrel, Aranesp marketing case
August 18, 2015 at 13:18 PM EDT
Aug 18 (Reuters) - Amgen Inc has reached a $71 million settlement with 48 U.S. states and the District of Columbia to resolve claims that the biotechnology company promoted its popular Enbrel and Aranesp drugs for uses not approved by the federal Food and Drug Administration.